This opportunity funds Stage 1 preliminary applications for clinical trials of gene-based and gene-targeted therapies aimed at ultra-rare neurological diseases. Trials are to be conducted within the NeuroNEXT network, focusing on advancing early-stage clinical research for these rare conditions.
